Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.

Détails

Ressource 1Télécharger: 28738904_BIB_F28D2598286B.pdf (911.25 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_F28D2598286B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.
Périodique
Journal of neuroinflammation
Auteur(s)
Lalive P.H., Kreutzfeldt M., Devergne O., Metz I., Bruck W., Merkler D., Pot C.
ISSN
1742-2094 (Electronic)
ISSN-L
1742-2094
Statut éditorial
Publié
Date de publication
24/07/2017
Peer-reviewed
Oui
Volume
14
Numéro
1
Pages
144
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Multiple sclerosis (MS) is an autoimmune disorder characterized by chronic inflammation, demyelination, and neuronal damage. During autoimmunity, cytokines are important mediators of the inflammation. In this line, interleukin-27 (IL-27) modulates inflammation and can be produced directly at inflammatory sites such as in the joints during rheumatoid arthritis or in the central nervous system (CNS) during MS. While in animal models of MS, treatment with IL-27 decreases the disease severity, its role in humans is not clearly established and it is not known if IL-27 could be detected in the cerebrospinal fluid (CSF) of MS patients.
In this study, we measured IL-27 levels using a quantitative enzyme-linked immunosorbent assay in CSF of patients with relapsing remitting multiple sclerosis (RRMS), isolated optic neuritis (ON) and non-inflammatory neurological disease (NIND) as well as in the sera of healthy donors (HD) and RRMS patients undergoing different disease modifying treatments. We further confirmed by immunohistology of patient biopsies the identity of IL-27 producing cells in the brain of active MS lesions.
We observed that IL-27 levels are increased in the CSF but not in the sera of RRMS compared to HD. We confirmed that IL-27 is expressed in active MS plaques by astrocytes of MS patients.
Our results point toward a local secretion of IL-27 in the CNS that is increased during autoimmune processes. We propose that local production of IL-27 could sign the induction of a regulatory response that promotes inflammation's resolution. The effect of new immunomodulatory therapies on cerebral IL-27 production could be used to understand the biology of IL-27 in MS disease.

Mots-clé
Adult, Astrocytes/metabolism, Astrocytes/pathology, Central Nervous System/metabolism, Central Nervous System/pathology, Female, Glial Fibrillary Acidic Protein/metabolism, Humans, Interleukin-27/blood, Interleukin-27/cerebrospinal fluid, Interleukin-27/metabolism, Interleukins/metabolism, Male, Middle Aged, Minor Histocompatibility Antigens/metabolism, Multiple Sclerosis/pathology, Oligoclonal Bands/metabolism, Severity of Illness Index, Statistics, Nonparametric, Young Adult, Cerebrospinal fluid, Cytokines, Immunohistochemistry, Interleukin-27, Multiple sclerosis
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/08/2017 11:01
Dernière modification de la notice
09/05/2019 3:22
Données d'usage